نتائج البحث - "JACOBSEN, TOVE FLEM"

1

Academic Journal

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course

المؤلفون: Rizzieri, David, Vey, Norbert, Thomas, Xavier, Huguet-Rigal, Françoise, Schlenk, Richard F., Krauter, Jürgen, Kindler, Thomas, Gjertsen, Bjørn Tore, Blau, Igor Wolfgang, Jacobsen, Tove Flem, Johansen, Malin, Bergeland, Trygve, Gianella-Borradori, Athos, Krug, Utz

المصدر: Leukemia & Lymphoma ; volume 55, issue 9, page 2114-2119 ; ISSN 1042-8194 1029-2403

الاتاحة: http://dx.doi.org/10.3109/10428194.2013.867489
http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.867489

View record in BASE

2

Academic Journal

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

المؤلفون: O'Brien, Susan, Rizzieri, David A., Vey, Norbert, Ravandi, Farhad, Krug, Utz O., Sekeres, Mikkael A., Dennis, Mike, Venditti, Adriano, Berry, Donald A., Jacobsen, Tove Flem, Staudacher, Karin, Bergeland, Trygve, Giles, Francis J.

مصطلحات موضوعية: elacytarabine, nucleoside analogue, lipid esterification, acute myelogenous leukemia, effective salvage regimen, fatty-acid derivatives, tumor-cell lines, g-csf, dose cytarabine, gemcitabine, cp-4055, expression, resistance

Relation: British Journal of Haematology; O'Brien, Susan; Rizzieri, David A. Vey, Norbert; Ravandi, Farhad; Krug, Utz O.; Sekeres, Mikkael A.; Dennis, Mike; Venditti, Adriano; Berry, Donald A.; Jacobsen, Tove Flem; Staudacher, Karin; Bergeland, Trygve; Giles, Francis J. (2012). Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. British Journal of Haematology 158 (5), 581-588; http://hdl.handle.net/10379/13169

الاتاحة: http://hdl.handle.net/10379/13169
https://doi.org/10.1111/j.1365-2141.2012.09186.x

View record in BASE

3

Academic Journal

Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

المؤلفون: Giles, Francis, Rizzieri, David, Ravandi, Farhad, Swords, Ronan, Jacobsen, Tove Flem, O’Brien, Susan

Relation: Leukemia Research; Giles, Francis; Rizzieri, David; Ravandi, Farhad; Swords, Ronan; Jacobsen, Tove Flem; O’Brien, Susan (2012). Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leukemia Research 36 (4), E71-E73; http://hdl.handle.net/10379/11635

الاتاحة: http://hdl.handle.net/10379/11635
https://doi.org/10.1016/j.leukres.2011.12.010

View record in BASE

4

Patent

Systems and Methods for Detecting hENT1 Expression in Hematological Disorders

View record in USPTO Patent Applications

5

Academic Journal

Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile

المؤلفون: Knapper, Steven, Chevassut, Timothy, Duarte, Rafael, Bergua, Juan Miguel, Salamero, Olga, Johansen, Malin, Jacobsen, Tove Flem, Hals, Petter-Arnt, Rasch, Wenche, Gianella-Borradorif, Athos, Smith, Matthew

مصطلحات موضوعية: R Medicine (General)

وصف الملف: application/pdf

Relation: http://sro.sussex.ac.uk/id/eprint/48628/1/Elacytarabine_paper.pdf; Knapper, Steven, Chevassut, Timothy, Duarte, Rafael, Bergua, Juan Miguel, Salamero, Olga, Johansen, Malin, Jacobsen, Tove Flem, Hals, Petter-Arnt, Rasch, Wenche, Gianella-Borradorif, Athos and Smith, Matthew (2014) Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research, 38 (3). pp. 346-351. ISSN 0145-2126

الاتاحة: http://sro.sussex.ac.uk/id/eprint/48628/
http://sro.sussex.ac.uk/id/eprint/48628/1/Elacytarabine_paper.pdf
https://doi.org/10.1016/j.leukres.2013.12.011

View record in BASE

6

Academic Journal

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

المؤلفون: Roboz, Gail J., Rosenblat, Todd, Arellano, Martha, Gobbi, Marco, Altman, Jessica K., Montesinos, Pau, O'Connell, Casey, Solomon, Scott R., Pigneux, Arnaud, Vey, Norbert, Hills, Robert Kerrin, Jacobsen, Tove Flem, Gianella-Borradori, Athos, Foss, Oivind, Vetrhusand, Sylvia, Giles, Francis J.

مصطلحات موضوعية: RC0254 Neoplasms. Tumors. Oncology (including Cancer)

Relation: Roboz, Gail J., Rosenblat, Todd, Arellano, Martha, Gobbi, Marco, Altman, Jessica K., Montesinos, Pau, O'Connell, Casey, Solomon, Scott R., Pigneux, Arnaud, Vey, Norbert, Hills, Robert Kerrin https://orca.cardiff.ac.uk/view/cardiffauthors/A038482J.html orcid:0000-0003-0166-0062 orcid:0000-0003-0166-0062, Jacobsen, Tove Flem, Gianella-Borradori, Athos, Foss, Oivind, Vetrhusand, Sylvia and Giles, Francis J. 2014. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology 32 (18) , pp. 1919-1926. 10.1200/JCO.2013.52.8562 https://doi.org/10.1200/JCO.2013.52.8562

الاتاحة: https://orca.cardiff.ac.uk/id/eprint/79570/
https://doi.org/10.1200/JCO.2013.52.8562

View record in BASE